Cellumed Co. Ltd (049180) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cellumed Co. Ltd (049180) has a cash flow conversion efficiency ratio of -0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-294.63 Million ≈ $-199.67K USD) by net assets (₩16.52 Billion ≈ $11.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cellumed Co. Ltd balance sheet quality to measure how much of total assets are equity-financed.
Cellumed Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cellumed Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 049180 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Cellumed Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellumed Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pyung Hwa Ind
KO:090080
|
0.402x |
|
Zaklady Magnezytowe Ropczyce S.A.
WAR:RPC
|
-0.006x |
|
Avalon Advanced Materials Ltd
TO:AVL
|
-0.024x |
|
Dabomb Protein
TWO:6578
|
0.000x |
|
JERSEY OIL+GAS PLC LS-01
F:TPC1
|
N/A |
|
Youil Energy Technology Co. Ltd.
KQ:340930
|
-0.002x |
|
Stablecoin Development Corporation
NYSE MKT:SDEV
|
0.100x |
|
Estrella Resources Ltd
AU:ESR
|
-0.064x |
Annual Cash Flow Conversion Efficiency for Cellumed Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cellumed Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Cellumed Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩8.78 Billion ≈ $5.95 Million |
₩-418.53 Million ≈ $-283.63K |
-0.048x | +79.65% |
| 2023-12-31 | ₩23.02 Billion ≈ $15.60 Million |
₩-5.40 Billion ≈ $-3.66 Million |
-0.234x | -48.97% |
| 2022-12-31 | ₩53.94 Billion ≈ $36.56 Million |
₩-8.49 Billion ≈ $-5.75 Million |
-0.157x | +30.01% |
| 2021-12-31 | ₩47.99 Billion ≈ $32.52 Million |
₩-10.79 Billion ≈ $-7.31 Million |
-0.225x | -108.37% |
| 2020-12-31 | ₩28.10 Billion ≈ $19.04 Million |
₩-3.03 Billion ≈ $-2.05 Million |
-0.108x | -218.21% |
| 2019-12-31 | ₩5.18 Billion ≈ $3.51 Million |
₩472.90 Million ≈ $320.48K |
0.091x | +217.96% |
| 2018-12-31 | ₩23.02 Billion ≈ $15.60 Million |
₩-1.78 Billion ≈ $-1.21 Million |
-0.077x | +43.15% |
| 2017-12-31 | ₩37.28 Billion ≈ $25.27 Million |
₩-5.07 Billion ≈ $-3.44 Million |
-0.136x | -48.08% |
| 2016-12-31 | ₩46.56 Billion ≈ $31.55 Million |
₩-4.28 Billion ≈ $-2.90 Million |
-0.092x | +17.86% |
| 2015-12-31 | ₩41.27 Billion ≈ $27.97 Million |
₩-4.62 Billion ≈ $-3.13 Million |
-0.112x | +15.92% |
| 2014-12-31 | ₩44.01 Billion ≈ $29.83 Million |
₩-5.86 Billion ≈ $-3.97 Million |
-0.133x | -1907.43% |
| 2013-12-31 | ₩49.20 Billion ≈ $33.34 Million |
₩362.28 Million ≈ $245.51K |
0.007x | -15.57% |
| 2012-12-31 | ₩48.75 Billion ≈ $33.04 Million |
₩425.13 Million ≈ $288.10K |
0.009x | -69.52% |
| 2011-12-31 | ₩31.75 Billion ≈ $21.52 Million |
₩908.37 Million ≈ $615.59K |
0.029x | -- |
About Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more